Diarrhea, vomiting, and constipation also occurred at higher rates in treatment groups
Retatrutide Phase 3 results look promising, but the drug is not FDA-approved for public use
Of patients taking GLP-1, 8.9% developed NAION compared to 1.8% of patients taking other medications
The availability of this pill could make weight-loss treatment more accessible to a large number of Americans who have avoided injectable options due to expense, discomfort with needles or rigid dosing rules
Get, to manage your symptom Get your, 4 Cr+ families benefitted Enter your Phone Number +91 | Enter a valid mobile number Send OTP OTP sent to 9988776655 Youve successfully subscribed to receive Get ready to feel your best
Not for human or veterinary use, self-administration, clinical, diagnostic, or therapeutic application